ColdZyme inactivates 99% of viruses causing common cold

An Oral spray ColdZyme contains a solution of proteolytic enzyme trypsin and glycerol, which happens to shorten the duration of the common cold and also reduces its gravity. A recent research by Enzymaticaa Swedish based life sciences company shows the clinical benefits of Enzyme-based oral spray that significantly impacts individual symptoms of sore throat, nose congestion, and headache.

First ever medicine for the treatment of a rare genetic disease

European Medicines Agency’s human medicines committee (CHMP) approves  Waylivra (Volanesorsen) for the treatment of a rare genetic disease- Familial chylomicronemia syndrome (FCS), which results in high levels of triglycerides in blood causing abdominal pain, potentially fatal attacks of acute pancreatitis, hepatosplenomegaly, diabetes, lack of concentration, memory loss and fat-filled spots on the skin (xanthomas). The medicine will help patients as there is no effective treatment available currently.

A common oral bacteria may accelerate the chances of Colon cancer

A recent research by Columbia University College of Dental Medicine has found out that a common oral bacteria F.nucleatum known for causing tooth decay increases the chances of getting diagnosed with Colon cancer. About a third of colorectal cancers are associated with the bacteria. F. nucleatum makes a molecule- FadA adhesion which triggers a signaling pathway in colon cells that only invigorates the growth of cancerous cells.

CEPI and CureVac to develop an mRNA vaccine printing platform

The Coalition for Epidemic Preparedness Innovations (CEPI) has joined hands with CureVac –a German biopharmaceutical firm which in the process of developing a transportable automated messenger RNA (mRNA) vaccine printing platform. The aim behind the printer is to print lipid-nanoparticle (LNP)-formulated mRNA vaccine for both known as well as unknown pathogens.

Celastrol intake proves to be an effective way to kill obesity

The recent findings by Umut Ozcan have revealed that an increasing amount of a receptor called IL1R1-a receptor present in Celastrol is responsible for its anti-obesity effect. The receptor receives signals from the cytokine interleukin 1 which acts as the gatekeeper for Celastrol’s metabolic actions.